Efficacy of dapoxetine in the treatment of premature ejaculation

Chris G McMahon, Chris G McMahon

Abstract

Introduction: Premature ejaculation (PE) is a common male sexual disorder which is associated with substantial personal and interpersonal negative psychological factors. Pharmacotherapy of PE with off-label antidepressant SSRI drugs is common. Development and regulatory approval of drugs specifically for the treatment of PE will reduce reliance on off-label treatments and serve to fill a unmet treatment need.

Aim: To review evidence supporting the efficacy and safety of dapoxetine in the treatment of PE.

Methods: MEDLINE and the proceedings of major international and regional scientific meetings during the period 1994-2010 were searched for publications or abstracts using the word dapoxetine in the title, abstract or keywords. This search was then manually cross-referenced for all papers. This review encompasses studies of dapoxetine pharmacokinetics, animal studies, human phase 1, 2 and 3 efficacy and safety studies and drug-interaction studies.

Results: Dapoxetine is a potent selective serotonin re-uptake inhibitor, which is administered on-demand 1-3 hours prior to planned sexual contact. Dapoxetine is rapidly absorbed and eliminated, resulting in minimal accumulation and has dose-proportional pharmacokinetics, which are unaffected by multiple dosing. Dapoxetine 30 mg and 60 mg has been evaluated in 5 randomized, double-blind, placebo-controlled studies in 6081 men aged ≥18 years. Outcome measures included stopwatch-measured intravaginal ejaculatory latency time (IELT), Premature Ejaculation Profile (PEP) inventory items, clinical global impression of change (CGIC) in PE, and adverse events. Mean IELT, all PEP items and CGIC improved significantly with both doses of dapoxetine vs. placebo (P < 0.001 for all). The most common treatment related adverse effects included nausea (11.0% for 30 mg, 22.2% for 60 mg), dizziness (586% for 30 mg, 10.9% for 60 mg), and headache (5.6% for 30 mg, 8.8% for 60 mg), and evaluation of validated rated scales demonstrated no SSRI class-related effects with dapoxetine use.

Conclusion: Dapoxetine, as the first drug developed for PE, is an effective and safe treatment for PE and represents a major advance in sexual medicine.

Keywords: dapoxetine; intravaginal ejaculatory latency time (IELT); premature ejaculation; selective serotonin re-uptake inhibitors (SSRIs).

Figures

Figure 1
Figure 1
Molecular structure of Dapoxetine: (+)-(S)-N,N-dimethyl-(α)- [2(1naphthalenyloxy)ethyl]-benzenemethanamine hydrochloride.
Figure 2
Figure 2
Plasma concentration profiles of dapoxetine after administration of a single dose or multiple doses of dapoxetine 30 mg (A) and dapoxetine 60 mg (B).
Figure 3
Figure 3
Intravaginal ejaculation latency times (IELT) at endpoint for baseline IELT ≤ 1 min and ≤0.5 min for placebo, dapoxetine 30 mg (IELT fold increase—

References

    1. Semans JH. Premature ejaculation: a new approach. South Med J. 1956;49:353–8.
    1. Masters WH, Johnson VE. Human Sexual Inadequacy. Boston: Little Brown; 1970.
    1. Jannini EA, Simonelli C, Lenzi A. Sexological approach to ejaculatory dysfunction. Int J Androl. 2002;25:317–23.
    1. Olivier B, van Oorschot R, Waldinger MD. Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int Clin Psychopharmacol. 1998;13:S9–14.
    1. Waldinger MD, Rietschel M, Nothen MM, Hengeveld MW, Olivier B. Familial occurrence of primary premature ejaculation. Psychiatr Genet. 1998;8:37–40.
    1. Pattij T, Olivier B, Waldinger MD. Animal models of ejaculatory behavior. Curr Pharm Des. 2005;11:4069–77.
    1. Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res. 2004;16:369–81.
    1. Metz ME, Pryor JL, Nesvacil LJ, Abuzzahab F, Sr, Koznar J. Premature ejaculation: a psychophysiological review. J Sex Marital Ther. 1997;23:3–23.
    1. Symonds T, Roblin D, Hart K, Althof S. How does premature ejaculation impact a man’s life? J Sex Marital Ther. 2003;29:361–70.
    1. Waldinger MD, Quinn P, Dilleen M, Mundayat R, Schweitzer DH, Boolell M. A Multinational Population Survey of Intravaginal Ejaculation Latency Time. J Sex Med. 2005;2:492–97.
    1. Patrick DL, Althof SE, Pryor JL, Rosen R, Rowland DL, Ho KF, et al. Premature Ejaculation: An Observational Study of Men and Their Partners. J Sex Med. 2005;2:58–367.
    1. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol. 2007;51:816–23.
    1. Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, et al. Premature ejaculation: results from a five-country European observational study. Eur Urol. 2008;53:1048–57.
    1. Reading A, Wiest W. An analysis of self-reported sexual behavior in a sample of normal males. Arch Sex Behav. 1984;13:69–83.
    1. Nathan SG. The epidemiology of the DSM-III psychosexual dysfunctions. J Sex Marital Ther. 1986;12:267–81.
    1. Spector KR, Boyle M. The prevalence and perceived aetiology of male sexual problems in a non-clinical sample. Br J Med Psychol. 1986;59:351–8.
    1. Spector IP, Carey M. Incidence and prevalence of the sexual dysfunctions: a critical review of the empirical literature. Arch Sex Behav. 1990;19:389.
    1. Grenier G, Byers ES. The relationships among ejaculatory control, ejaculatory latency, and attempts to prolong heterosexual intercourse. Arch Sex Behav. 1997;26:27–47.
    1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537–44.
    1. Schapiro B. Premature ejaculation, a review of 1130 cases. J Urol. 1943;50:374–79.
    1. Jern P, Santtila P, Witting K, Alanko K, Harlaar N, Johansson A, et al. Premature and delayed ejaculation: genetic and environmental effects in a population-based sample of Finnish twins. J Sex Med. 2007;4:1739–49.
    1. Janssen PK, Bakker SC, Rethelyi J, Zwinderman AH, Touw DJ, Olivier B, et al. Serotonin transporter promoter region (5-HTTLPR) polymorphism is associated with the intravaginal ejaculation latency time in Dutch men with lifelong premature ejaculation. J Sex Med. 2009;6:276–84.
    1. Hartmann U, Schedlowski M, Kruger TH. Cognitive and partner- related factors in rapid ejaculation: Differences between dysfunctional and functional men. World J Urol. 2005;10:10.
    1. Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, et al. Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res. 2005;17:39–57.
    1. Screponi E, Carosa E, Di Stasi SM, Pepe M, Carruba G, Jannini EA. Prevalence of chronic prostatitis in men with premature ejaculation. Urology. 2001;58:198–202.
    1. Carani C, Isidori AM, Granata A, Carosa E, Maggi M, Lenzi A, et al. Multicenter Study on the Prevalence of Sexual Symptoms in Male Hypoand Hyperthyroid Patients. J Clin Endocrinol Metab. 2005;90:6472–79.
    1. Adson DE, Kotlyar M. Premature ejaculation associated with citalopram withdrawal. Ann Pharmacother. 2003;37:1804–6.
    1. Peugh J, Belenko S. Alcohol, drugs and sexual function: a review. J Psychoactive Drugs. 2001;33:223–32.
    1. McMahon CG, Althof SE, Waldinger MD, Porst H, Dean J, Sharlip ID, et al. An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation. J Sex Med. 2008;5:1590–606.
    1. Porst H, McMahon CG, Althof SE, Sharlip I, Bull S, Aquilina JW, et al. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials. J Sex Med. 2010 Apr 20; [Epub ahead of print.]
    1. Althof SE, Abdo CH, Dean J, Hackett G, McCabe M, McMahon CG, et al. International Society for Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med. 7:2947–69.
    1. McMahon C, Abdo C, Incrocci L, Perelman M, Rowland D, Waldinger M, et al. Disorders of orgasm and ejaculation in men. J Sex Med. 2004;1
    1. Rowland D, McMahon CG, Abdo C, Chen J, Jannini E, Waldinger MD, et al. Disorders of orgasm and ejaculation in men. J Sex Med. 7:1668–86.
    1. Salonia A, Rocchini L, Sacca A, Pellucchi F, Ferrari M, Carro UD, et al. Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. J Sex Med. 2009;6:2868–77.
    1. McMahon CG. Long term results of treatment of premature ejaculation with selective serotonin re-uptake inhibitors. Int JImp Res. 2002;14:S19.
    1. Sorbera LA, Castaner J, Castaner RM. Dapoxetine hydrochloride. Drugs Future. 2004;29:1201–1205.
    1. Gengo RJ, Giuliano F, McKenna KE, Chester A, Lovenberg T, Bonaventure P, et al. Monoaminergic Transporter Binding and Inhibition Profile of Dapoxetine, A medication for the Treatment of Premature Ejaculation. J Urol. 2005;173:230. , abstract 878.
    1. Livni E, Satterlee W, Robey RL, Alt CA, Van Meter EE, Babich JW, et al. Synthesis of [11C]dapoxetine. HCl, a serotonin re-uptake inhibitor: biodistribution in rat and preliminary PET imaging in the monkey. Nucl Med Biol. 1994;21:669–75.
    1. Dresser MJ, Lindert K, Lin D. Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clin Pharmacol Ther. 2004;75:113. , abstract P1.
    1. Dresser MJ, Kang D, Staehr P, Gidwani S, Guo C, Mulhall JP, et al. Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: Impact of age and effects of a high-fat meal. J Clin Pharmacol. 2006;46:1023–9.
    1. Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S. Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol. 2006;46:301–9.
    1. Thyssen A, Sharma O, Tianmei S, Aquilina JW, Vandebosch A, Wang SS, et al. Pharmacokinetics of Dapoxetine Hydrochloride in Healthy Chinese, Japanese, and Caucasian Men. J Clin Pharmacol. 2010 Jan 23; [Epub ahead of print.]
    1. Clement P, Bernabe J, Gengo P, Denys P, Laurin M, Alexandre L, et al. Supraspinal site of action for the inhibition of ejaculatory reflex by dapoxetine. Eur Urol. 2007;51:825–32.
    1. Clement P, Bernabe P, Gengo P, Roussel D, Giuliano F. Dapoxetine inhibits p-Chloroamphetamine-induced ejaculation in Anesthetized Rats. J Sex Med. 2006
    2. Book of Abstracts—8th Congress of the European Society for Sexual Medicine; abstract P-02–159.
    1. Giuliano F, Bernabe J, Gengo P, Alexandre L, Clement P. Effect of acute dapoxetine administration on the pudendal motoneuron reflex in anesthetized rats: comparison with paroxetine. J Urol. 2007;177:386–9.
    1. Gengo PJ, Marson L, Gravitt A. Actions of Dapoxetine in Ejaculation and Sexual Behaviour in Rats. J Sex Med. 2006
    2. Book of Abstracts—8th Congress of the European Society for Sexual Medicine; abstract MP-01–74.
    1. Hellstrom WJ, Gittelman M, Althof S. Dapoxetine HCl for the treatment of premature ejaculation: A Phase II, randomised, double-blind, placebo controlled study. J Sex Med. 2004;1(Suppl 1):59. , abstract 097.
    1. Hellstrom WJ, Althof S, Gittelman M, Streidle C, Ho KF, Kell S, et al. Dapoxetine for the treatment of men with premature ejaculation (PE): dose-finding analysis. J Urol. 2005;173:238. , abstract 877.
    1. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006;368:929–37.
    1. Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F. Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol. 2009;55:957–67.
    1. Kaufman JM, Rosen RC, Mudumbi RV, Tesfaye F, Hashmonay R, Rivas D. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int. 2009;103:651–8.
    1. McMahon C, Kim SW, Park NC, Chang CP, Rivas D, Tesfaye F, et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med. 2010;7:256–68.
    1. Porst H, McMahon C, Althof S, Sharlip I, Bull S, Aquilina J, et al. Baseline characteristics and treatment outcome for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: Integrated analyses of three phase 3 dapoxetine trials. J Sex Med. 2010 Accepted for Publication.
    1. Patrick DL, Giuliano F, Ho KF, Gagnon DD, McNulty P, Rothman M. The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practice. BJU Int. 2009;103:358–64.
    1. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Geometric Mean IELT and Premature Ejaculation: Appropriate Statistics to Avoid Overestimation of Treatment Efficacy. J Sex Med. 2008;5:492–99.
    1. McMahon CG. Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies—part II—study design, outcome measures, data analysis, and reporting. J Sex Med. 2008;5:1817–33.
    1. Byers ES, Grenier G. Premature or rapid ejaculation: heterosexual couples’ perceptions of men’s ejaculatory behavior. Arch Sex Behav. 2003;32:261–70.
    1. Metz ME, Pryor JL. Premature ejaculation: a psychophysiological approach for assessment and management. J Sex Marital Ther. 2000;26:293–320.
    1. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62:10–21.
    1. Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. J Psychopharmacol. 1997;11:72–82.
    1. Public assessment report scientific discussion: priligy dapoxetine hydrochloride film-coated tablets, 30 and 60 mg. Läkemedelsverket Medical Products Agency; Dec, 2008. [[2011 May 25.]]. Available from URL: .
    1. Modi NB, Nath R, Staehr P, Gupta SK, Aquilina JW, Rivas D. Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects. J Clin Pharmacol. 2009;49:634–42.
    1. McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JW, et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med. 2010;8:524–39.
    1. Shabsigh R, Patrick DL, Rowland DL, Bull SA, Tesfaye F, Rothman M. Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine. BJU Int. 2008;102:824–8.
    1. Ng GA. Treating patients with ventricular ectopic beats. Heart. 2006;92:1707–2.
    1. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996;16:356–62.
    1. Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry. 1997;58:291–7.
    1. Tamam L, Ozpoyraz N. Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv Ther. 2002;19:17–26.
    1. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160:790–2.
    1. Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA, Goodwin FK, et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology. 2006;31:473–92.
    1. Zajecka J, Fawcett J, Schaff M, Jeffriess H, Guy C. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry. 1991;52:66–8.
    1. Ditto KE. SSRI discontinuation syndrome. Awareness as an approach to prevention. Postgrad Med. 2003;114:79–84.
    1. Black K, Shea CA, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2000;25:255–61.
    1. Waldinger MD. Premature ejaculation: definition and drug treatment. Drugs. 2007;67:547–68.
    1. Modi NB, Dresser M, Desai D, Edgar C, Wesnes K. Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. J Clin Pharmacol. 2007;47:315–22.
    1. Dresser MJ, Desai D, Gidwani S, Seftel AD, Modi NB. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int J Impot Res. 2005
    1. Modi NB, Kell S, Aquilina J, Rivas D. Effect of dapoxetine on the pharmacokinetics and hemodynamic effects of tamsulosin in men on a stable dose of tamsulosin. J Clin Pharmacol. 2008;48:1438–50.
    1. McMahon CG, Althof SE, Waldinger MD, Porst H, Dean J, Sharlip ID, et al. An Evidence-Based Definition of Lifelong Premature Ejaculation: Report of the International Society for Sexual Medicine (ISSM) Ad Hoc Committee for the Definition of Premature Ejaculation. J Sex Med. 2008
    1. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Proposal for a Definition of Lifelong Premature Ejaculation Based on Epidemiological Stopwatch Data. J Sex Med. 2005;2:498–507.
    1. Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, et al. Premature Ejaculation: Results from a Five-Country European Observational Study. [Accessed 2007 Oct 16];Eur Urol. [Epub ahead of print.]
    1. Waldinger M, Hengeveld M, Zwinderman A, Olivier B. An empirical operationalization of DSM-IV diagnostic criteria for premature ejaculation. Int J Psychiatry Clin Pract. 1998;2:287–93.
    1. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. The majority of men with lifelong premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men. J Sex Med. 2007;4:1028–37.
    1. McMahon CG, Abdo C, Incrocci I, Perelman M, Rowland D, Stuckey B, et al. Disorders of orgasm and ejaculation in men. In: Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F, editors. Sexual Medicine: Sexual Dysfunctions in Men and Women (2nd International Consultation on Sexual Dysfunctions-Paris) Paris, France: Health Publications; 2004. pp. 409–68.
    1. Waldinger MD, Berendsen HH, Blok BF, Olivier B, Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res. 1998;92:111–8.
    1. Waldinger M. Towards evidenced based drug treatment research on premature ejaculation: a critical evaluation of methodology. J Impotence Research. 2003;15:309–13.
    1. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021–6.
    1. Atmaca M, Kuloglu M, Tezcan E, Semercioz A. The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002;14:502–5.
    1. McMahon CG. Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol. 1998;159:1935–8.
    1. Kara H, Aydin S, Yucel M, Agargun MY, Odabas O, Yilmaz Y. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol. 1996;156:1631–2.
    1. Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 1994;151:1377–9.
    1. Goodman RE. An assessment of clomipramine (Anafranil) in the treatment of premature ejaculation. J Int Med Res. 1980;8:53–9.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться